Table 7 Adverse events in ≥ 3 patients overall by system organ class and preferred term events.
From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
System Organ Classa Preferred Term | Cycle 1 (n = 74)b | Cycle 2 (n = 61) | Cycle 3 (n = 38) | Cycle 4 (n = 32) | Cycle 5 (n = 19) | Cycle 6 (n = 18) | >Cycle 6 (n = 15) | Overall (N = 74) |
|---|---|---|---|---|---|---|---|---|
Blood and Lymphatic System Disorders | 24 (32.4)c | 17 (27.9) | 11 (28.9) | 9 (28.1) | 5 (26.3) | 3 (16.7) | 4 (26.7) | 41 (55.4) |
Anaemiad | 14 (18.9) | 9 (14.8) | 6 (15.8) | 3 (9.4) | 1 (5.3) | 1 (5.6) | 2 (13.3) | 29 (39.2) |
Thrombocytopeniae | 8 (10.8) | 3 (4.9) | 3 (7.9) | 6 (18.8) | 5 (26.3) | 2 (11.1) | 4 (26.7) | 18 (24.3) |
Neutropeniaf | 8 (10.8) | 3 (4.9) | 6 (15.8) | 1 (3.1) | 3 (15.8) | 0 | 2 (13.3) | 14 (18.9) |
Leukopeniag | 1 (1.4) | 2 (3.3) | 3 (7.9) | 1 (3.1) | 1 (5.3) | 0 | 1 (6.7) | 7 (9.5) |
Cardiac Disorders | 2 (2.7) | 2 (3.3) | 0 | 0 | 1 (5.3) | 0 | 0 | 5 (6.8) |
Palpitations | 2 (2.7) | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 3 (4.1) |
Ear and Labyrinth Disorders | 11 (14.9) | 4 (6.6) | 5 (13.2) | 0 | 1 (5.3) | 0 | 1 (6.7) | 19 (25.7) |
Tinnitus | 8 (10.8) | 3 (4.9) | 4 (10.5) | 0 | 0 | 0 | 0 | 13 (17.6) |
Hypoacusis | 3 (4.1) | 2 (3.3) | 2 (5.3) | 0 | 0 | 0 | 0 | 5 (6.8) |
Eye Disorders | 4 (5.4) | 3 (4.9) | 5 (13.2) | 1 (3.1) | 2 (10.5) | 0 | 3 (20.0) | 13 (17.6) |
Vision blurred | 0 | 2 (3.3) | 1 (2.6) | 1 (3.1) | 1 (5.3) | 0 | 1 (6.7) | 6 (8.1) |